SynthesisFrontiers in aging neuroscience2025
Glutamate-associated research in Parkinson's disease: a bibliometric analysis.
Synthesis in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Sphingolipids associated research in Alzheimer's disease: an explored trends analysis.Frontiers in aging neuroscience · 2026Pooled it
- Microglia associated research in depression: an exploratory trends analysis.Frontiers in aging neuroscience · 2026Pooled it
- Insulin-like growth factor 1 associated research in Alzheimer's disease: an exploratory trends analysis.Frontiers in neurologyPooled it
- Deltex 2 Mediates Oxidative Stress and Neurotoxicity in Freezing of Gait of Parkinson's Disease via the Notch2-Nrf2 Axis.CNS neuroscience & therapeutics · 2026Article
- Synthetic Cyclic CAntioxidants (Basel, Switzerland) · 2026Article
- Astrocytes in Parkinson's Disease: From Guardians to Accomplices.Clinical interventions in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is a common neurodegenerative disease. As an important excitatory neurotransmitter, glutamate plays a key role in the nervous system. The imbalance of glutamate levels, the dysfunction of related receptors, and the abnormal activity of transporters are closely associated with the pathological process of PD. This study aims to explore the research hotspots, frontiers, and development directions of PD and glutamate. Method: The relevant publications were obtained from the Web of Science. CiteSpace, VOSviewer, and bibliometrix were used for visualization and quantitative evaluation. Results: A total of 2,488 publications related to the research topic were included. From 2001 to 2024, the annual number of publications showed a fluctuating upward trend. The United States was a leader in this field, working closely with China, Italy, the United Kingdom, and France. Karolinska Institute was the most active institution. Core journals were mainly related to neuroscience, covering basic research, clinical applications, and pharmacology. Dr. Conn, P. Jeffrey was the most productive author. The paper " Conclusion: Research on PD and glutamate focused on countries with increasing aging. The collaboration of different countries and institutions was conducive to promoting the development of this field. The research hotspots included basal ganglia, oxidative stress, DA, neurons, a-Syn, glutamate receptors, and synaptic plasticity. a-Syn and neuroinflammation may be research directions in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.